Kerrisdale Advisers, LLC Delcath Systems, Inc. Transaction History
Kerrisdale Advisers, LLC
- $273 Million
- Q4 2024
A detailed history of Kerrisdale Advisers, LLC transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Kerrisdale Advisers, LLC holds 66,645 shares of DCTH stock, worth $929,031. This represents 0.29% of its overall portfolio holdings.
Number of Shares
66,645
Previous 17,967
270.93%
Holding current value
$929,031
Previous $162,000
384.57%
% of portfolio
0.29%
Previous 0.06%
Shares
2 transactions
Others Institutions Holding DCTH
# of Institutions
95Shares Held
11MCall Options Held
144KPut Options Held
57.4K-
Vivo Capital, LLC Palo Alto, CA1.71MShares$23.8 Million3.93% of portfolio
-
Aigh Capital Management LLC Baltimore, MD1.39MShares$19.3 Million6.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.22MShares$17.1 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT801KShares$11.2 Million0.66% of portfolio
-
Gilder Gagnon Howe & CO LLC New York, NY612KShares$8.53 Million0.08% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $120M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...